BioWorld MedTech

March 27, 2013

AdreView approved for risk evaluation in HF patients

GE Healthcare (Princeton, New Jersey) reported FDA approval of a new indication for AdreView (Iobenguane I 123 Injection), a molecular imaging agent, to link nerve function in the heart to a patient's mortality risk. Read More

Johns Hopkins students develop simple, effective cooling device

Report from Europe: Miracor treats German patient with PICSO

Washington roundup: McConnell to House; vote on stand-alone device tax repeal

Agreements/contracts: PrimeraDx to co-develop diagnostics with Quest

Deals roundup: ICCNexergy in plan to acquire Applied Power

HIT roundup: TGen tests secure connection using Obsidian's Longbow tech

Financings roundup: Medgenics reports exercise of over-allotment option

Product Briefs

People in the News

MDD's Oncology Extra

Today's news in brief

BioWorld

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...